Objective: To identify risk factors associated with disease recurrence among Filipinos with papillary thyroid carcinoma (PTC).
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The primary treatment of PTC is still surgery (thyroidectomy) and when appropriate, a neck dissection. 3, 4, 5 In our setting, a considerable subset of PTC tends to become more aggressive and recurs even with adequate surgical and medical management. While local and regional recurrences of PTC after surgery have ranged from 5-10%, 6 a 2010 study among Filipinos with thyroid cancer claimed recurrence rates as high as 25%. 7 Recurrences may be local (primary site and adjacent structures), regional (cervical lymph nodes) or distant and impact negatively on patients' quality of life with increased morbidity.
The extent of surgery and need for adjuvant treatment depend on several prognostic factors that influence risk stratification of patients in terms of recurrence and survival. Several studies have identified clinicopathologic factors predictive of increased risk of recurrence among patients with PTC, including age, sex, tumor size, cervical lymph node metastasis, extrathyroidal invasion, bilaterality/multifocality and post-operative RAI therapy. 8 -17 In order to determine specific patient-and disease-related factors associated with PTC recurrence among our patient population that are essential for developing initial treatment and follow-up schemes and establishing the need for adjuvant treatment in our setting, this study aims to determine factors that are associated with recurrence of PTC among patients admitted at PGH-ORL in terms of age during initial surgery, sex, tumor size, multifocality, extrathyroidal extension, lymph node metastasis and post-operative RAI therapy.
METHODS
With institutional review board approval, this retrospective cohort study reviewed the records of 86 patients diagnosed with papillary thyroid carcinoma that underwent total thyroidectomy with or without neck dissection at the PGH-ORL from January 2010 to December 2014 and followed up for at least 10 months. Papillary thyroid carcinoma recurrence was defined as the reappearance of PTC after a period of at least 10 months from initial surgery including both local and regional recurrences. 7 Medical records (including operative records and histopathology results) were reviewed for the following data: age (years) at the time of initial surgery, sex, tumor size, multifocality, extrathyroidal extension, lymph node metastasis, post-operative RAI therapy and length of follow-up. Considered for inclusion were records of patients with Papillary Thyroid Cancer on histopathologic result and low and lowto-intermediate risk 2015 ATA classification. Excluded were records of cases with no definite histopathologic result and high-risk 2015 American Thyroid Association (ATA) classification (residual disease, gross extrathyroidal extension, distant metastasis) as these patients had high risk of recurrence. 18 Data was tabulated using Microsoft Excel version 2013 (Microsoft, Chicago, USA) and means and proportions were obtained. Univariate analysis was performed using log-rank test. The outcome of interest was recurrence, established by imaging (ultrasonography or computed tomography), thyroglobulin levels, thyroid scintigraphy, or histopathology. Variables with p < .25 on univariate analysis were included in the multivariate analysis using Cox regression. KaplanMeier curves were obtained. Data were analyzed using STATA version 13.1 (StataCorp, TX, USA).
RESULTS
Records of 76 patients (21 males, 55 females) were included in this series. The mean age of the patients was 44 ± 2 years (range 15-77 years). The average tumor size was 3.96 ± 0.29 cm (range 0.3 to 14.5 cm). 29 (38.15%) had recurrences while 47 had no observed recurrence on the cut-off date. The sites of recurrences follows: 3, thyroid bed only; 17, lateral neck (16 unilateral and 1 bilateral); 9, both thyroid bed and lateral neck (6 in the thyroid bed and unilateral neck and 3 in the thyroid bed and bilateral neck). The 10 excluded records were those of 2 patients that had no definite histopathologic result and 8 cases with high risk 2015 ATA classification. Table 1 summarizes the clinicopathologic profiles of the patients included in the series.
With cut-off p < .25, age (p = .01), tumor size (p = .2), multifocality (p = .04), extrathyroidal extension (p = .02), presence of lateral neck nodes (p = .03) and RAI therapy (p = .2) were included in multivariate analysis on which no clinicopathologic factor was statistically associated with recurrence. This indicates that other factors affecting recurrence are missing in the model (R 2 =0.3776). Table 2 summarizes the results (p values, hazards ratios and confidence intervals) of both univariate and multivariate logistic regression analyses on the factors studied.
In this study, those with age > 45 years old had 1.93 times higher risk of having a recurrence than those </= 45 years old . Tumor size of >2 to 4 cm and >4 cm had 59% and 74% increased risk of recurrence compared to tumors <2 cm in size, respectively. The presence of multifocality increased the risk of recurrence by 69%. The risk of recurrence was 1.31 times higher if extrathyroidal extension was present. Unilateral neck nodes and bilateral neck nodes increased the risk of recurrence 2.06 times and 1.47 times, respectively. RAI therapy decreased the risk of recurrence by 51%. Figure 1 shows the Kaplan-Meier curve analysis for each clinicopathologic factor studied. The estimated 5-year recurrencefree estimate is 32.87%. 
DISCUSSION
This study suggests that age of >45 years, female sex, tumor size of >2 cm, multifocality, presence of extrathyroidal extension and lymph node metastasis may increase the risk of papillary thyroid recurrence although the associations did not reach statistical significance. Postoperative RAI ablation may decrease the risk of recurrence although this also did not reach statistical significance. (Table 2 ) These factors are similar to reports in other populations.
11,16
The 45-year-old age cut-off by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology was also shown to be a risk factor for papillary thyroid cancer recurrence among Filipi nos in this study. 4 In this study, PTC patients with multifocal disease had higher risk of developing recurrence than those with unifocal disease. This echoes the findings of Qu et al. 19 that increasing number of tumor foci of PTC are associated with a tendency toward more aggressive features, shorter recurrence-free survival and may be a possible indicator of cancer death. The number of tumor foci might also represent the tumor burden in PTC patients, 19 consistent with another study by Lin et al. where 52.9% of recurrent multicentric PTC patients were diagnosed within the first year of thyroidectomy. 20 This study showed that extrathyroidal extension carries an increased risk of developing recurrence. In comparison, Arora et al. found a 6.4-fold increased risk D E F G of recurrence and significantly decreased disease-free survival in PTC patients with macroscopic extrathyroidal extension 21 and nodal metastasis has been reported to increase the risk of recurrence. 19, 21 The use of post-operative RAI therapy based on our results is protective with an HR of 0.49. Unlike in high risk patients where the evidence for the benefits of RAI are strong, the ATA 2015 guideline reported that there are conflicting observational data in the use of postop RAI among low and low-to intermediate risk patients. 18 According to the UP-PGH Revised Clinical Practice Guidelines for the Management of Well-Differentiated Thyroid Carcinoma of Follicular Cell Origin in 2012, the use of adjuvant RAI treatment in well-differentiated thyroid cancer has been shown to significantly decrease disease recurrence and causespecific mortality. 5 Our study supports this recommendation. There are several limitations of this study. First is the potential for selection bias in a retrospective study. In this study, it was assumed that all tumors were resected if no residual tumor was indicated in the operative technique or no positive margins were noted on histopathologic result. Initial thyroglobulin levels were not available for all patients. Second, the timing of recurrence is relative. For some patients, recurrence was detected due to regular determination of thyroglobulin. For some, imaging was done after a neck mass was noted. In effect, the diagnosis of recurrence might be later than it really is. This could decrease the possible relationship of recurrence to the variables studied. Third, the variables measured in this study were limited to age (years) at the time of initial surgery, sex, tumor size, multifocality, microscopic extrathyroidal extension, lymph node metastasis and post-operative RAI therapy. Other variables that could affect recurrence like molecular mutation status and timeliness of RAI therapy were not measured.
In conclusion, age of >45 years, female sex, tumor size of >2 cm, multifocality, presence of microscopic extrathyroidal extension and lymph node metastasis might contribute to the recurrence of papillary thyroid cancer while post-operative radioactive ablation may have some protective effect. However, the findings in this study suggest that other factors must be included in the model in order to better understand the relationship between these factors and recurrence.
